logo
logo
Sign in

Growing demand for biologics development solutions is anticipated to open up new avenues for the biopharma buffer market

avatar
Gauri Cmi
Growing demand for biologics development solutions is anticipated to open up new avenues for the biopharma buffer market



The biopharma buffer market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Biopharma buffers are utilized in numerous biopharmaceutical applications such as cell cultivation, chromatography, drug formulation, and analytical techniques. They help maintain the optimal pH in various processes involved in biologics development and manufacturing. Common biopharma buffers used are phosphate buffered saline (PBS), tris buffered saline (TBS), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). They play a vital role in regulating the pH and solubility of proteins, enzymes, and other biomolecules.

Market Dynamics:

Increasing investments by biopharmaceutical companies in R&D of novel biologics is a key factor driving the growth of the  Global Biopharma Buffer Market. According to statistics by PhRMA, the biopharmaceutical industry invested over US$ 102 billion in 2020 for medical and biological R&D. Additionally, rapid expansion of contract manufacturing and generic drug production fueled by patent expiries of blockbuster drugs is augmenting the demand for biopharma buffers. Adoption of single-use technologies and continuous bioprocessing also require buffers to maintain optimal operating conditions, thus boosting market growth. Another driver is the rising government focus on development of cell and gene therapies worldwide, which is leading to increasing demand for biopharma buffers in downstream processing of cell culture media.

Segment Analysis

The biopharma buffer market is segmented based on product type, end user and geography. By product type, the market is segmented into phosphate buffers, tris buffers, acetate buffers and others. Among these, phosphate buffers dominate the market as they are most commonly used in maintaining pH and optimal conditions for protein stability during protein purification, cell culture and downstream processing. By end user, the market is divided into research institutes, pharmaceutical & biotechnology companies and contract research organizations. Pharmaceutical & biotechnology companies garner the highest share due to high usage of buffers for manufacturing biologics and biopharmaceuticals.

PEST Analysis

Political: Stringent regulations regarding quality and approval processes for biologics boost the demand for biopharma buffers that ensure optimal conditions.

Economic: Rising R&D investments in biologics and biosimilars by biopharma companies fuel the market growth.

Social: Growing awareness about chronic diseases and increasing demand for targeted biologic therapies facilitate market expansion.

Technological: Advancements in upstream and downstream processing methods require specialized buffers to maintain pH and viability of biologic molecules during various stages of bioproduction.

Key Takeaways

The global biopharma buffer market is expected to witness high growth, exhibiting CAGR of 7.1% over the forecast period, due to increasing demand for biologics and boosting R&D in biopharmaceutical industry. The market size for 2023 is US$ 3.68 Bn.

By region, North America leads the biopharma buffer market and is expected to maintain its dominance during the forecast period. This is attributed to presence of major pharmaceutical companies and high healthcare expenditure in the region.

Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation. Key players are focusing on developing advanced buffers to cater therapeutic applications in cell and gene therapy and emerging modalities.

 

Read More: https://www.rapidwebwire.com/biopharma-buffer-market-share/


collect
0
avatar
Gauri Cmi
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more